Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis

被引:0
|
作者
Mao Yinjun
Wang Weiwei
Ma Jun
Wu Shanshan
Sun Feng
机构
[1] Beijing Digestive Disease Center
[2] Peking University Health Science Center
[3] School of Public Health
[4] ChinaNational Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders
[5] Department of Pharmacy
[6] Beijing 100088
[7] Beijing Friendship Hospital
[8] Beijing Key Laboratory for Precancerous Lesion of Digestive Disease
[9] Capital Medical University
[10] Fuzhou
[11] Peking University Health Science Centre
[12] ChinaInstitute of Basic Medical Sciences
[13] National Clinical Research Center for Digestive Disease
[14] First Affiliated Hospital of Fujian Medical University
[15] Beijing 100191
[16] ChinaDepartment of Epidemiology and Biostatistics
[17] Beijing Anding Hospital
[18] ChinaDepartment of Gastroenterology
[19] Fujian 350005
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
COVID-19; Reinfection; SARS-COV-2; Rate;
D O I
暂无
中图分类号
R563.1 [肺炎];
学科分类号
1002 ; 100201 ;
摘要
Background: Asymptomatic or symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be followed by reinfection. The protection conferred by prior infection among coronavirus disease 2019 (COVID-19) patients is unclear. We assessed the incidence of SARS-CoV-2 reinfection and the protection effect of previous infection against reinfection.Methods: We searched PubMed, EMBASE, Cochrane, Scopus, Web of Science, and ClinicalTrials.gov for publications up until the end date of May 1, 2021. The reinfection rate of recovered patients and the protection against reinfection were analyzed using meta-analysis.Results: Overall, 19 studies of 1096 reinfection patients were included. The pooled reinfection rate was 0.65% (95% confidence interval [CI] 0.39-0.98%). The symptomatic reinfection rate was a bit lower (0.37% [95% CI 0.11-0.78%],I2 = 99%). The reinfection rate was much higher in high-risk populations (1.59% [95% CI 0.30-3.88%],I2= 90%). The protection against reinfection and symptomatic reinfection was similar (87.02% [95% CI 83.22-89.96%] and 87.17% [95% CI 83.09-90.26%], respectively).Conclusions: The rate of reinfection with SARS-CoV-2 is relatively low. The protection against SARS-CoV-2 after natural infection is comparable to that estimated for vaccine efficacy. These data may help guide public health measures and vaccination strategies in response to the COVID-19 pandemic. High-quality clinical studies are needed to establish the relevant risk factors in recovered patients.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 50 条
  • [1] Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis
    Mao, Yinjun
    Wang, Weiwei
    Ma, Jun
    Wu, Shanshan
    Sun, Feng
    CHINESE MEDICAL JOURNAL, 2022, 135 (02) : 145 - 152
  • [2] Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis
    Luojia Deng
    Peiqi Li
    Xuezhixing Zhang
    Qianxue Jiang
    DeAnne Turner
    Chao Zhou
    Yanxiao Gao
    Frank Qian
    Ci Zhang
    Hui Lu
    Huachun Zou
    Sten H. Vermund
    Han-Zhu Qian
    Scientific Reports, 12
  • [3] Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis
    Deng, Luojia
    Li, Peiqi
    Zhang, Xuezhixing
    Jiang, Qianxue
    Turner, DeAnne
    Zhou, Chao
    Gao, Yanxiao
    Qian, Frank
    Zhang, Ci
    Lu, Hui
    Zou, Huachun
    Vermund, Sten H.
    Qian, Han-Zhu
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis
    Nguyen, Nhu Ngoc
    Nguyen, Y. Ngoc
    Hoang, Van Thuan
    Million, Matthieu
    Gautret, Philippe
    VIRUSES-BASEL, 2023, 15 (04):
  • [5] Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis
    Ng, Wern Hann
    Tipih, Thomas
    Makoah, Nigel A.
    Vermeulen, Jan-G
    Goedhals, Dominique
    Sempa, Joseph B.
    Burt, Felicity J.
    Taylor, Adam
    Mahalingam, Suresh
    MBIO, 2021, 12 (01): : 1 - 12
  • [6] Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
    Yang, Jing
    Zheng, Ya
    Gou, Xi
    Pu, Ke
    Chen, Zhaofeng
    Guo, Qinghong
    Ji, Rui
    Wang, Haojia
    Wang, Yuping
    Zhou, Yongning
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 94 : 91 - 95
  • [7] Effect of antitumor therapy on cancer patients infected by SARS-CoV-2: A systematic review and meta-analysis
    Li, Piao
    Li, Lingling
    Wang, Shennan
    Liu, Yu
    Li, Zhou
    Xia, Shu
    CANCER MEDICINE, 2021, 10 (05): : 1644 - 1655
  • [8] Colorectal cancer in patients with SARS-CoV-2: a systematic review and meta-analysis
    Saad Alhumaid
    Abbas Al Mutair
    Jawad S. Busubaih
    Nourah Al Dossary
    Murtadha Alsuliman
    Sarah A. Baltyour
    Ibrahim Alissa
    Hassan I. Al Hassar
    Noor A. Al Aithan
    Hani A. Albassri
    Suliman A. AlOmran
    Raed M. ALGhazal
    Ahmed Busbaih
    Nasser A. Alsalem
    Waseem Alagnam
    Mohammed Y. Alyousef
    Abdulaziz U. Alseffay
    Hussain A. Al Aish
    Ali Aldiaram
    Hisham A. Al eissa
    Murtadha A. Alhumaid
    Ali N. Bukhamseen
    Koblan M. Al mutared
    Abdullah H. Aljwisim
    Abdullah M. Twibah
    Meteab M. AlSaeed
    Hussien A. Alkhalaf
    Fatemah M. ALShakhs
    Thoyaja Koritala
    Jaffar A. Al-Tawfiq
    Kuldeep Dhama
    Ali A. Rabaan
    Awad Al-Omari
    Infectious Agents and Cancer, 17
  • [9] Diabetic ketoacidosis in patients with SARS-CoV-2: a systematic review and meta-analysis
    Saad Alhumaid
    Abbas Al Mutair
    Zainab Al Alawi
    Ali A. Rabaan
    Mohammed A. Alomari
    Sadiq A. Al Salman
    Ahmed S. Al-Alawi
    Mohammed H. Al Hassan
    Hesham Alhamad
    Mustafa A. Al-kamees
    Fawzi M. Almousa
    Hani N. Mufti
    Ali M. Alwesabai
    Kuldeep Dhama
    Jaffar A. Al-Tawfiq
    Awad Al-Omari
    Diabetology & Metabolic Syndrome, 13
  • [10] Colorectal cancer in patients with SARS-CoV-2: a systematic review and meta-analysis
    Alhumaid, Saad
    Al Mutair, Abbas
    Busubaih, Jawad S.
    Al Dossary, Nourah
    Alsuliman, Murtadha
    Baltyour, Sarah A.
    Alissa, Ibrahim
    Al Hassar, Hassan, I
    Al Aithan, Noor A.
    Albassri, Hani A.
    AlOmran, Suliman A.
    ALGhazal, Raed M.
    Busbaih, Ahmed
    Alsalem, Nasser A.
    Alagnam, Waseem
    Alyousef, Mohammed Y.
    Alseffay, Abdulaziz U.
    Al Aish, Hussain A.
    Aldiaram, Ali
    Al Eissa, Hisham A.
    Alhumaid, Murtadha A.
    Bukhamseen, Ali N.
    Al Mutared, Koblan M.
    Aljwisim, Abdullah H.
    Twibah, Abdullah M.
    AlSaeed, Meteab M.
    Alkhalaf, Hussien A.
    ALShakhs, Fatemah M.
    Koritala, Thoyaja
    Al-Tawfiq, Jaffar A.
    Dhama, Kuldeep
    Rabaan, Ali A.
    Al-Omari, Awad
    INFECTIOUS AGENTS AND CANCER, 2022, 17 (01)